A nurse practitioner discussed considerations for managing aromatase inhibitor-related joint pain in patients with breast ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

Treatment decisions are based on clinical efficacy. However, the role of economics in the selection of medical interventions is increasing, especially health care systems. This refers not only to ...

In a recent webinar, Dalia Rosano Imperial College London) discussed breast cancer and epigenetic combination therapies.

While ESR1 mutations are rare in untreated patients, they occur in approximately 40% of patients after they received ...

Researchers found that 44.8% of the 357 patients exhibited coronary artery calcium; groups had no significant difference in aromatase inhibitor treatment duration. HealthDay News — For ...

Adjuvant ribociclib plus an aromatase inhibitor is now an FDA-approved treatment in HR-positive, HER2-negative stage II and III early breast cancer at a high risk of recurrence. The FDA has approved ...

New evidence shows that extended estrogen suppression treatment using aromatase inhibitors for hormone receptor-positive postmenopausal breast cancer is safe; it does not increase the risk of ...

In postmenopausal women, there is still some production of the hormone estrogen even though the ovaries have largely shut down. Drugs called aromatase inhibitors are used to block the activity of the ...

For patients with hormone receptor (HR)-positive, HER2-negative early breast cancer, the combination of Kisqali (ribociclib) and nonsteroidal aromatase inhibitor (NSAI) therapy resulted in sustained ...

I have been on an aromatase inhibitor for the past eight months and have side effects that keep me from having a good quality of life. I am supposed to be on it for five years, but I do not want to ...

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a high risk of recurrence. The Food and Drug Administration (FDA) has approved ...